What is it about?
Each human genome is unique and the first WGS or WES studies published revealed a wide heterogeneity in the cancer genome sequence among patients with the same organ-specific and tumor–node–metastasis stage. Over the next few years, with the completion of tissue-based WGS/WES from thousands of cancer patients by the International Cancer Genome Consortium and other projects, a causal mutation-based landscape will emerge for each cancer type, promising the development of new taxonomy-based personalized genetic characterization and treatment of cancer.
Featured Image
Why is it important?
These techniques provide unprecedented deep insights into the cancer genome structure and function, shaping the future of personalized oncology.
Perspectives
Beyond the clinical success of trastuzumab, emerging research emphasis is focused on how to develop novel robust biomarkers for improving the tailoring of available targeted drugs and on how to develop the next generation of inhib-itors of the network of signaling pathway inter-actions. Although the time has not yet arrived for wide clinical implementation of NGS and other omics technologies, these techniques provide unprecedented deep insights into the cancer genome structure and function, shaping the future of personalized oncology.
Dr Demosthenes E. Ziogas
Peripheral General Hospital of Ioannina - Xatzikosta
Read the Original
This page is a summary of: Emerging personalized oncology: sequencing and systems strategies, Future Oncology, June 2012, Future Medicine,
DOI: 10.2217/fon.12.44.
You can read the full text:
Contributors
The following have contributed to this page
